| Literature DB >> 33431669 |
Corleone S Delaveris1,2, Shannon H Chiu1,2, Nicholas M Riley1, Carolyn R Bertozzi3,2,4.
Abstract
Inflammatory pathologies caused by phagocytes lead to numerous debilitating conditions, including chronic pain and blindness due to age-related macular degeneration. Many members of the sialic acid-binding immunoglobulin-like lectin (Siglec) family are immunoinhibitory receptors whose agonism is an attractive approach for antiinflammatory therapy. Here, we show that synthetic lipid-conjugated glycopolypeptides can insert into cell membranes and engage Siglec receptors in cis, leading to inhibitory signaling. Specifically, we construct a cis-binding agonist of Siglec-9 and show that it modulates mitogen-activated protein kinase (MAPK) signaling in reporter cell lines, immortalized macrophage and microglial cell lines, and primary human macrophages. Thus, these cis-binding agonists of Siglecs present a method for therapeutic suppression of immune cell reactivity.Entities:
Keywords: Siglec; glycocalyx; glycopolymer; immunotherapy; inflammation
Mesh:
Substances:
Year: 2021 PMID: 33431669 PMCID: PMC7826350 DOI: 10.1073/pnas.2012408118
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 12.779